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Abstract: We have developed a miniature human liver (liver-sinusoid-on-a-chip) model using a dual
microchannel separated by a porous membrane. Primary human hepatocytes and immortalized
bovine aortic endothelial cells were co-cultured on opposite sides of a microporous membrane in a
dual microchannel with continuous perfusion. Primary human hepatocytes in this system retained
their polygonal morphology for up to 26 days, while hepatocytes cultured in the absence of bovine
aortic endothelial cells lost their morphology within a week. In order to demonstrate the utility of
our human-liver-sinusoid-on-a-chip, human hepatocytes in this system were directly infected by
Hepatitis B Virus (HBV). Expression of the HBV core antigen was detected in human hepatocytes in
the microchannel system. HBV replication, measured by the presence of cell-secreted HBV DNA,
was also detected. Importantly, HBV is hepatotropic, and expression of HBV RNA transcripts
is dependent upon expression of hepatocyte-specific factors. Moreover, HBV infection requires
expression of the human-hepatocyte-specific HBV cell surface receptor. Therefore, the ability to
detect HBV replication and Hepatitis B core Antigen (HBcAg) expression in our microfluidic platform
confirmed that hepatocyte differentiation and functions were retained throughout the time course of
our studies. We believe that our human-liver-sinusoid-on-a-chip could have many applications in
liver-related research and drug development.
Keywords: liver sinusoid; human-liver-sinusoid-on-a-chip; Hepatitis B virus (HBV); HBV replication
study; hepatocyte; microfluidic platform

1. Introduction
The World Health Organization has estimated that approximately 240 million people in the
world have a chronic Hepatitis B Virus (HBV) infection of the liver [1,2]. A chronic HBV infection
has been linked to the development of severe liver diseases, including hepatitis, cirrhosis, and
hepatocellular carcinomas [3]. Liver inflammation associated with immune-mediated destruction of
HBV-infected hepatocytes, integration of the HBV genome into the host genome, and the activities
of HBV genome-encoded proteins have all been proposed as potential mechanisms that underlie the
development of HBV-associated diseases; however, there are still significant gaps in our understanding
of how a chronic HBV infection can lead to the development of severe liver diseases [4,5]. One reason

Micromachines 2017, 8, 27; doi:10.3390/mi8010027

www.mdpi.com/journal/micromachines

Micromachines 2017, 8, 27

2 of 13

for this gap in our knowledge is the absence of in vitro human hepatocyte culture systems that
mimic the environment and cellular architecture of the liver and can be used for long-term studies
of the consequence of an HBV infection to human hepatocyte physiology. The development of
these types of systems is critical for providing platforms that can be used to define HBV effects on
hepatocyte physiology.
Many studies intent on understanding the biology of liver diseases and liver damage by toxins or
infectious agents have been carried out using animal models or established cell lines due to the limited
availability of normal human liver cells [6]. Moreover, because the host range of HBV is very narrow,
the available animal models that can be directly infected by HBV are limited; for example, mice and rats
cannot be directly infected by HBV [7,8]. Unfortunately, expression of the recently discovered human
HBV receptor in rodent hepatocytes does not render these susceptible to an HBV infection [9]. Although
in vitro liver cell culture models exist, these systems typically consist of immortalized hepatocyte cell
lines that do not represent authentic differentiated hepatocytes and typically have altered signaling
pathways [10,11]. As a result, attempts to analyze the consequences of an HBV infection may not
be accurately represented in these in vitro systems. Unfortunately, primary hepatocytes quickly
de-differentiate when hepatocytes are isolated from the liver and cultured in traditional cell-culture
formats, limiting their use in long-term studies [12,13]. Moreover, these conventional cell culture
platforms, containing only hepatocytes, do not provide a physiological environment where hepatocytes
constantly interact with other types of liver cells. Hence, there remains a need to develop an in vitro
primary human liver model that is a physiologically relevant model for liver research.
Many attempts have been made with the help of microfabrication and microfluidics
technologies to develop more accurate in vitro human liver models that can recapitulate the in vivo
microenvironment and architecture of the liver [14–18]. However, none of these have yet been able to
successfully facilitate long-term liver-related disease studies. In our previous studies, we successfully
demonstrated a microchannel-based in vitro assay for studying HBV replication in a single-layer
microchannel containing primary rat hepatocytes or HepG2 cells under static culture conditions [19].
More recently, we presented a rat liver sinusoid model that consisted of two microchannels simulating
the blood sinusoid and bile duct (Figure 1) [20]. The two microchannels were separated by a porous
membrane with hepatocytes and endothelial cells cultured on the opposite sides of the membrane.
We demonstrated the long-term (over 30 days) maintenance of primary rat hepatocytes differentiation
and functions when the hepatocytes were co-cultured with endothelial cells. We also used this system
as a novel platform for studying HBV replication, although the initial infection of the rat hepatocytes
by HBV could not be studied because rat hepatocytes are not directly susceptible to HBV infection and
this initial stage of infection had to be bypassed by delivering the HBV genome to the hepatocytes via
a recombinant adenovirus containing a replication-competent copy of the HBV genome.
Our goal in the present study was to show that human hepatocytes could be co-cultured with
endothelial cells in a similar microfluidic platform as in our previous studies, and that human
hepatocytes in this system retain their differentiation status and functions for long-term culture
and can be directly infected by HBV. To this end, we present a human-liver-sinusoid-on-a-chip model
that is created by extending our dual microchannel platform with primary rat hepatocytes to a
primary human hepatocyte culture system. We further demonstrate the utility of our liver model by
demonstrating that human hepatocytes in this system can be directly infected with HBV (Figure 1).
Human hepatocytes are the natural site of an HBV infection, and, although there are many
aspects of the HBV lifecycle that are understood, there are still major gaps in our understanding of
precisely how HBV infects hepatocytes and replicates in these cells (Figure 1). An impediment to fully
understanding all aspects of the HBV lifecycle has been the paucity of available human hepatocyte
systems that allow for a direct HBV infection that can be monitored and analyzed for a longer time than
in conventional primary hepatocyte culture systems. The recent identification of the human-hepatocyte
cell-surface HBV receptor is likely to further enhance our understanding of mechanisms that regulate
HBV entry into hepatocytes [21]. The HBV genome is a highly compact, partially double stranded,
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2. Materials and Methods
2.1. Fabrication of Microfluidic Platforms
Templates for rectangular microchannels (approximately 15 mm long, 1 mm wide, and 600–800 µm
high) were fabricated via the stereolithography technique with PhotoSilver 130 (EnvisionTEC GmbH,
Gladbeck, Germany) resin and the Envision Tec® Perfectory SXGA+ Standard UV Stereolithography
system [20,29]. Polydimethylsiloxane (PDMS) microchannels were then made by the replica-molding
method using the 3-dimensional (3D)-printed microchannel templates [19]. Two PDMS microchannels
were treated with air plasma at 65 W for 70 s (Femtoscience, Yongin, Korea) and bonded together with
a microporous polyethyleneterephthalate (PET) membrane (10 µm thick with a pore size of 0.4 µm)
placed between them (Figure 1) [29,30]. The bonded dual-channel was wrapped with Kapton tape
(Micronova, Torrance, CA, USA) for complete sealing. Inlet and outlet ports of the microchannels
were made by implanting silicone tubes during PDMS replica molding. The bottom surface of
the microchannel and the PET membrane were coated with collagen type I, and the assembled
microchannel device was then sterilized using ultraviolet (UV) light as previously described [20].
2.2. Layered Co-Culture of Primary Human Hepatocytes and Endothelial Cells
Normal primary human hepatocytes in suspension were obtained through the Liver Tissue Cell
Distribution System, Pittsburgh, Pennsylvania, which is funded by National Institutes of Health
Contract #HHSN276201200017C. The cells were cultured in Dulbecco’s Modified Eagle Media (DMEM,
Cellgro, Mediatech, Manassas, VA, USA), supplemented with 1 mM sodium pyruvate (Cellgro),
4 µg/mL insulin-transferrin-selenium (ITS, Gibco, Thermo Fisher Scientific, Waltham, MA, USA),
5 µg/mL hydrocortisone (HC, Sigma, St. Louis, MO, USA), 5 ng/mL epidermal growth factor
(EGF, BD Sciences, San Jose, CA, USA), 1% penicillin-streptomycin, and 10% (v/v) fetal bovine serum
(FBS, Gemini Bioproducts, West Sacramento, CA, USA) at 37 ◦ C in 5% CO2 .
Bovine aortic endothelial cells (BAECs) are immortalized, microvascular, endothelial cells that can
be passaged repeatedly [31]. Because these cells are more readily available than primary human
liver sinusoidal endothelial cells, we chose to use BAECs in our system as a proof-of-concept,
wherein co-culture primary human hepatocytes and endothelial cells facilitated long-term survival
and maintenance of hepatocyte differentiation. The BAECs were a kind gift from Dr. Robert Levy
(Children’s Hospital of Philadelphia) [30]. The isolation and characterization of BAECs have been
previously described [31]. BAECs were cultured in DMEM, supplemented with 10% (v/v) FBS
and 1% (v/v) penicillin-streptomycin (Cellgro) at 37 ◦ C in 5% CO2 . For the layered co-culture,
approximately 1 × 104 –2 × 104 primary human hepatocytes with 70%–100% viability were plated
in the collagen-coated microchannel using a pipette by slowly adding them from one side of the
microchannel until the fluid began to exit from the other side of the microchannel. Cells adhered
to the microporous membrane and formed a confluent monolayer by 24 h after plating, referred
to as Day 1. The device was then flipped over and endothelial cells were plated on the opposite
side of the microporous membrane and allowed to adhere for another 24 h. The device was then
connected to a syringe pump to provide continuous perfusion of the culture medium with a flow rate
of 30–40 µL/h (Figure 1). The flow rate was determined based on both the experimental observation
of cell morphology under a range of flow rate 0–100 µL/h and the estimated shear stress as described
in our previous study [20]. Multiple valves were placed downstream of the microchannel outlet to
facilitate sampling of the flow-through medium. When not sampled, the culture medium coming out
of the microchannel was collected into a waste bottle.
2.3. Live-Dead Staining and Imaging
The viability of primary human hepatocytes cultured in the microchannel was examined using a
LIVE/DEAD Viability/Cytotoxicity Kit according to the manufacturer’s directions (ThermoFisher,
Waltham, MA, USA). Briefly, the primary human hepatocytes were stained with calcein-AM (5 mg/mL)
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and ethidium bromide (2.5 mg/mL) fluorescent stains for 15 min at 37 ◦ C. Images were acquired using
an inverted fluorescence microscope.
2.4. Source, Purification, and Quantification of Infectious HBV
Infectious HBV was isolated from the cell-culture supernatants of the HBV-producing cell lines,
HepG2.215 or HepAD38 cells [32,33]. HBV-producing cell lines were seeded at 80% confluency
and maintained for 7–10 days with a replenishment of medium every 2–3 days. Virus containing
cell-culture supernatants were pooled and then cleared of cellular debris by centrifugation at 3000× g
for 10 min. HBV was precipitated from pooled supernatants as described previously [34], with some
modifications. Briefly, supernatants were polyethylene glycol 8000 (PEG8000) precipitated overnight
at 4 ◦ C, followed by centrifugation at 3000× g for 30 min to pellet PEG8000-precipitated material.
Pellets containing infectious HBV were resuspended in DMEM at a volume equivalent to 1/10 of
the starting cell-culture supernatant volume. A small portion of the concentrated stock was set aside
and subjected to a standard polymerase chain reaction (PCR) with HBV-specific primers, following
isolation of HBV DNA using the QIamp DNA Blood Mini Kit (Qiagen, Hilden, Germany) according to
the manufacturer’s instructions. PCR analysis of dilutions of the plasmid pGEMHBV, which contains a
DNA copy of the HBV genome, was used to create a standard curve for calculating genome equivalents
(GE) present in precipitated HBV stocks; GE were calculated by comparing the intensity of viral stock
PCR products observed following electrophoresis in an agarose gel to the intensity of PCR products in
the standard curve.
2.5. Infection of Primary Human Hepatocytes with HBV or Recombinant Adenoviruses
Hepatocytes are naturally infected with HBV that is introduced into the liver sinusoid via the
blood stream (Figure 1); however, because our goal was to demonstrate that hepatocytes cultured in
our system can be directly infected by HBV, we directly introduced HBV into the bottom channel,
where hepatocytes are cultured in order to improve the efficiency of viral infection. In a natural
infection, HBV likely passes through the fenestrae of liver sinusoid endothelial cells (LSECs) to
directly infect hepatocytes, and there is no evidence that HBV is transported through LSECs to infect
hepatocytes. Hence, the direct infection method that we have used is consistent with a natural
HBV infection. Infection of primary human hepatocytes in microchannels was carried out using
concentrated HBV stocks, as described previously [35], at a genome equivalent of 250–500 per cell.
An infection medium containing HBV, 2% DMSO and 4% PEG8000 was added to the microchannel
without the introduction of flow for 16–18 h, and then the cells were washed three times with
phosphate-buffered saline (PBS) and maintained in growth medium containing 2% DMSO [35].
Recombinant adenoviruses encoding either a humanized recombinant green fluorescent protein
(hrGFP) alone adenovirus encoding green fluorescent protein (AdGFP) or hrGFP and a cDNA of
the HBV genome (AdGFP-HBV) were used to demonstrate that the hepatocytes were susceptible
to a viral infection and capable of expressing HBV proteins. Due to the extensive overlap of open
reading frames and the condensed nature of the HBV genome, the cDNA of HBV contains all HBV
genes expressed from transcription promoters that are also part of the cDNA and hence require
maintenance of the hepatocyte differentiation status for expression. The construction and use of
these adenoviruses has been previously described [36]. For infection, 30–40 µL of the adenovirus
solution was added slowly from one end of the microchannel until the solution began to exit the
other end of the microchannel. The primary human hepatocytes were incubated with the recombinant
adenovirus without introduction of flow for 16–18 h and washed as described above for the direct
HBV infection. Fresh primary human hepatocyte medium was then introduced to the microchannels.
The liver-sinusoids-on-a-chip with either AdGFP- or AdGFP-HBV-infected hepatocytes was connected
to a perfusion system and maintained at 37 ◦ C in 5% CO2 . Expression of HBV core antigen was
assessed approximately 10–14 days after AdGFP-HBV infection.
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2.6. Analysis of Secreted HBV DNA
For HBV studies, we used the microchannel devices containing the layered co-culture of primary
human hepatocytes and BAECs; hepatocytes were infected with HBV as described above. The medium
from the HBV-infected and control uninfected hepatocytes in microchannels was collected at the
indicated time points and stored at −80 ◦ C for detection of HBV genome by PCR, as described below.
Fluid samples of 1–2 mL were collected from each microchannel over the course of an entire day;
PEG8000/1.5 M NaCl (30% (w/v)) was then added for the precipitation of secreted HBV. The final
concentration of PEG8000 in a mixed sample was 8% (w/v). After incubation of these samples at 4 ◦ C
for approximately 16 h, HBV virions were obtained by centrifugation of the samples at 15,000× g
for 15 min, followed by resuspension of the pellet in 50 µL PBS. The pelleted virions were then
incubated with 1.5 µL of DNase I (10 mg/mL) and 0.5 µL of 1 M MgCl2 for one hour at 37 ◦ C and
then mixed with 5 µL of 0.5 M EDTA, 10 µL of 10% SDS, 0.2 µL of 2 M CaCl2 , and 2.5 µL of proteinase
K at 10 mg/mL. After incubation for 1–2 h at 55 ◦ C, the samples were centrifuged at 15,000× g for
15 min and supernatants were mixed with 0.3 µL of 3 M sodium acetate (pH 4.8–5.2) and 75 µL of
chilled 100% ethanol and stored at −20 ◦ C overnight. The HBV genome was precipitated by a 15 min
centrifugation at 15,000× g, and the pellet was resuspended in 20 µL of deionized water. The pelleted
HBV genome was then analyzed by PCR using HBV-specific primers (568 bp product) as previously
described [19,20]. As a positive control for detection of the HBV genome, a plasmid including the HBV
genome was used.
2.7. Immunofluorescence Assay
After culturing HBV or recombinant adenovirus infected primary human hepatocytes for the
indicated times, the dual microchannel was disconnected from the perfusion system and disassembled
for assessment of the HBV core protein expression by immunofluorescence. The PET membrane that
cells adhered to was placed on a microscope glass slide. The primary human hepatocytes cultured
on the PET membrane were washed and incubated with 95% ethanol and 5% acetic acid mixture at
−20 ◦ C overnight to permeabilize and fix the cells. The cells were then washed twice with 2% bovine
serum albumin (BSA) in PBS solution and then dried for 20 min after the 2% BSA solution was
removed. The cells were incubated for 1 h at room temperature with an anti-HBV core antibody
(HBcAb, SC-23945, Santa Cruz Biotechnology, Dallas, TX, USA) diluted in 2% BSA. After incubation,
the cells were washed four times with 2% BSA in PBS. The cells were then incubated with a donkey
anti-mouse IgG (Alexa fluor 594, Cat #A21203, Life Technologies, Carlsbad, CA, USA) for 1 h at room
temperature, followed by three washes with PBS and one with water. Mounting medium including
40 ,6-diamidino-2-phenylindole (DAPI) nuclear staining dye was added to the cells, and the cells were
observed with a fluorescence microscope.
2.8. Image Assay
The average fluorescence intensity of the virus-infected cells from fluorescent microscopy images
was quantified using ImageJ (NIH, Bethesda, MD, USA). Briefly, the background of images was
subtracted, the image contrast was enhanced, and the average fluorescence intensity was measured
using built-in ImageJ functions [16].
3. Results and Discussion
3.1. Primary Human Hepatocyte-Only Culture and Co-Culture of Hepatocytes and BAECs
Primary human hepatocytes were cultured in the absence of other cells in a single microchannel
under static culture conditions; these hepatocytes maintained their polygonal morphology for about
3 days, after which this morphology was lost (Figure 2a,b). When primary human hepatocytes-only
were cultured on a microporous membrane of a dual-PDMS microchannel under continuous perfusion,
these hepatocytes maintained a normal phenotype in the microchannel for about 5–7 days after seeding,
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their combination.
normal hepatocyte morphology for at least
hepatocyte
would
be the
most
physiologically
relevant

When primary human hepatocytes and BAECs were co-cultured in our microchannel platform
by layering on opposite sides of the microporous membrane, the cells formed a confluent monolayer
and the primary human hepatocytes maintained their normal hepatocyte morphology for at least
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three
weeks
(Figure
2f).Primary
Primaryhuman
humanhepatocytes
hepatocytes at
at the
top
were
layered
three
weeks
(Figure
2f).
the bottom
bottomand
andBAECs
BAECsatatthe
the
top
were
layered
microchannel. To
To further
further investigate
viability
of primary
human
hepatocytes
coin in
thethe
microchannel.
investigatethe
theextended
extended
viability
of primary
human
hepatocytes
cultured
with
BAECs,
we
continued
to
observe
the
co-cultured
cells
for
26
days
and
also
assessed
the
co-cultured with BAECs, we continued to observe the co-cultured cells for 26 days and also assessed
KitKit
(Molecular
probes).
theviability
viabilityofofthe
thehepatocytes
hepatocytesusing
usingthe
theLIVE/DEAD
LIVE/DEADViability/Cytotoxicity
Viability/Cytotoxicity
(Molecular
probes).
Figure 2g,h show the green fluorescent (live cells) and red fluorescent (dead cells) images of primary
Figure 2g,h show the green fluorescent (live cells) and red fluorescent (dead cells) images of primary
human hepatocytes. In contrast with primary human hepatocytes-only culture, this result indicates
human hepatocytes. In contrast with primary human hepatocytes-only culture, this result indicates
that primary human hepatocytes remain viable for at least 26 days when co-cultured with BAECs in
that primary human hepatocytes remain viable for at least 26 days when co-cultured with BAECs in
microchannels under flow conditions. In addition, this result agrees with the findings from others
microchannels under flow conditions. In addition, this result agrees with the findings from others that
that primary hepatocytes show better viability and function when co-cultured with other cell types,
primary
hepatocytes
betterHowever,
viability and
function
when
co-cultured
with
other cell
types, such
such as
fibroblasts show
[13,37,38].
we did
note that
the
cells did not
maintain
a confluent
as monolayer
fibroblasts over
[13,37,38].
However,
we
did
note
that
the
cells
did
not
maintain
a
confluent
the entire surface of the microchannel at day 26, and partial detachment ofmonolayer
the cells
over
the
entire
surface
of
the
microchannel
at
day
26,
and
partial
detachment
of
the
cells
was
noticed.
was noticed.

3.2.3.2.
Infection
of of
Primary
Adenovirusesand
andExpression
ExpressionofofHBV
Infection
PrimaryHuman
HumanHepatocytes
Hepatocyteswith
with Recombinant
Recombinant Adenoviruses
HBV Core Antigen
Core Antigen
In In
ourour
human
liver model, only about ten-thousand cells were plated on the small dimensions of
human liver model, only about ten-thousand cells were plated on the small dimensions
theofmicrochannel
surface.
WeWe
next
investigated
of primary
primaryhuman
humanhepatocytes
hepatocytes
the microchannel
surface.
next
investigatedififthe
thesmall
smallnumber
number of
cultured
in
this
limited
area
could
be
infected
with
viruses,
providing
supportive
evidence
cultured in this limited area could be infected with viruses, providing supportive evidence forfor
thethe
useuse
of of
our
model
for
studying
viral
infections
of
hepatocytes,
such
as
an
HBV
infection,
and
potential
our model for studying viral infections of hepatocytes, such as an HBV infection, and potential
mechanisms
Forthis
thisinvestigation,
investigation,wewefirst
first
used
mechanismsthat
thatlink
linkthese
theseviral
viralinfections
infections to
to liver
liver disease.
disease. For
used
infection
with
adenovirusinstead
instead
direct
infection
of primary
human
hepatocytes
infection
withrecombinant
recombinant adenovirus
of of
direct
infection
of primary
human
hepatocytes
with
with
HBV.
This
because
infection
with
AdGFP
can
provide
preliminary
information
regarding
viral
HBV.
This
is is
because
infection
with
AdGFP
can
provide
preliminary
information
regarding
viral
infection
of of
primary
ofGFP
GFPininthe
theinfected
infectedcells,
cells,
such
how
infection
primaryhepatocytes
hepatocytesby
bychecking
checking the
the expression
expression of
such
as as
how
many
virus
infected-hepatocytes
in the
microchannel.
Initially
we tested
this
the primary
many
virus
infected-hepatocytes
areare
in the
microchannel.
Initially
we tested
this in
theinprimary
human
human hepatocytes-only
culture
the single microchannel.
We infected
hepatocytes
in the
hepatocytes-only
culture in the
single in
microchannel.
We infected hepatocytes
in the
microchannels
with
microchannels
with
AdGFP
on
day
2
after
plating.
The
virus
was
incubated
in
the
microchannel
AdGFP on day 2 after plating. The virus was incubated in the microchannel for approximately 16 h,for
and
approximately
then the medium
in the microchannel
was removed,
cells hepatocyte
were washed,
and
then
the medium 16
in h,
theand
microchannel
was removed,
cells were washed,
and fresh
medium
fresh
hepatocyte
was added. Primary
hepatocytes
infected
was
added.
Primarymedium
human hepatocytes
infected human
with AdGFP
expressed
GFP with
for atAdGFP
least 48expressed
h following
GFP
for
at
least
48
h
following
infection
(Figure
3a,
green
fluorescence
image)
[39].
The resulted
infection in
infection (Figure 3a, green fluorescence image) [39]. The infection efficiency of AdGFP
efficiency of AdGFP resulted in approximately 69.4% of primary human hepatocytes expressing GFP;
approximately 69.4% of primary human hepatocytes expressing GFP; cells were imaged by fluorescence
cells were imaged by fluorescence microscopy and analyzed by ImageJ for quantification of
microscopy and analyzed by ImageJ for quantification of fluorescence intensity. As a result, we verified
fluorescence intensity. As a result, we verified that the small number of primary human hepatocytes
that the small number of primary human hepatocytes in the limited microchannel area were infected
in the limited microchannel area were infected with the virus with about 70% of viral infection
with the virus with about 70% of viral infection efficiency. Result shown in Figure 3a is from a single
efficiency. Result shown in Figure 3a is from a single microchannel; similar infection efficiency was
microchannel; similar infection efficiency was noted in a replicate sample.
noted in a replicate sample.

Figure 3. Primary human hepatocytes infected with recombinant adenovirus. (a) Green fluorescence
Figure 3. Primary human hepatocytes infected with recombinant adenovirus. (a) Green fluorescence
image of primary human hepatocytes infected with AdGFP in the single microchannel (day 4 after
image of primary human hepatocytes infected with AdGFP in the single microchannel (day 4 after cell
cell plating); (b) Green fluorescence image of primary human hepatocytes infected with AdGFP-HBV
plating); (b) Green fluorescence image of primary human hepatocytes infected with AdGFP-HBV in a
in a dual microchannel (day 5 after cell plating). Scale bar: 400 μm.
dual microchannel (day 5 after cell plating). Scale bar: 400 µm.

We next sought to determine whether HBV proteins could be expressed from the HBV genome
next sought
to microchannel
determine whether
proteins could
beexpression
expressed of
from
HBV
in We
hepatocytes
in our
system.HBV
We specifically
tested
the the
HBV
coregenome
antigen in
as a surrogate
marker
of HBV protein
expression.
We infected
hepatocytes
inof
thethe
microchannel
with
hepatocytes
in our
microchannel
system.
We specifically
tested
expression
HBV core antigen
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as a surrogate marker of HBV protein expression. We infected hepatocytes in the microchannel with
a recombinant
adenovirus
as aa cDNA
cDNAof
ofthe
theHBV
HBVgenome
genome
(AdGFP-HBV).
a recombinant
adenovirusthat
thatencoded
encoded GFP
GFP as
as well
well as
(AdGFP-HBV).
Expression
of of
allall
HBV
controlledby
byHBV-specific
HBV-specifictranscription
transcription
promoters
Expression
HBVproteins
proteinsfrom
fromthe
thecDNA
cDNA is controlled
promoters
and
relies
onon
the
differentiation
Ourgoal
goalwas
wastotoshow
showexpression
expression
HBV
and
relies
the
differentiationstatus
statusof
ofthe
thehepatocytes.
hepatocytes. Our
of of
HBV
proteins
controlled
by
an
endogenous
HBV
transcription
promoter
in
our
co-culture
system
and
proteins controlled by an endogenous HBV transcription promoter in our co-culture system and wewe
initially
used
the
AdGFP-HBVbecause
because of
of the
the high efficiency
ofof
hepatocytes.
initially
used
the
AdGFP-HBV
efficiencyof
ofadenovirus
adenovirusinfection
infection
hepatocytes.
Since
requires
a longer
time
period
HBVproteins
proteinstotobebedetectable
detectablehepatocytes,
hepatocytes, as
as compared
compared to
Since
thisthis
requires
a longer
time
period
forforHBV
to
GFP
expression,
for
these
studies
with
AdGFP-HBV,
we
used
primary
human
hepatocytes
coGFP expression, for these studies with AdGFP-HBV, we used primary human hepatocytes co-cultured
cultured
with
BAECs
in
the
dual
microchannel
system.
Hepatocytes
were
first
added
to
the
with BAECs in the dual microchannel system. Hepatocytes were first added to the microchannels,
microchannels,
followed
BAECs on
of the
membrane,
and the were
hepatocytes
were
followed
by BAECs
on thebyopposite
of the
the opposite
membrane,
and
the hepatocytes
infected
with
infected
with
AdGFP-HBV
on
day
2
after
hepatocytes
plating
[8,40].
The
microchannels
were
then
AdGFP-HBV on day 2 after hepatocytes plating [8,40]. The microchannels were then connected
to a perfusion
continuoussystem.
perfusionThe
system.
cells infected
with AdGFP-HBV
after
to connected
a continuous
cells The
infected
with AdGFP-HBV
on dayon2 day
after2 plating
plating maintained a GFP expression for 3 days after infection (Figure 3b). Analysis and
maintained a GFP expression for 3 days after infection (Figure 3b). Analysis and quantification
quantification of the GFP expression using ImageJ demonstrated an infection efficiency of
of the GFP expression using ImageJ demonstrated an infection efficiency of approximately 56.5% of the
approximately 56.5% of the primary human hepatocytes by AdGFP-HBV. This efficiency is a little
primary human hepatocytes by AdGFP-HBV. This efficiency is a little lower compared to the infection
lower compared to the infection efficiency of AdGFP. However, this infection efficiency is consistent
efficiency of AdGFP. However, this infection efficiency is consistent with results of our previous
with results of our previous studies, in which we showed that adenovirus infection efficiency of
studies,
in which we showed that adenovirus infection efficiency of primary rat hepatocytes ranges
primary rat hepatocytes ranges from 30% to 70% [20]. Approximately 12 days after infection with
from
30%
to 70%the
[20].
Approximately
12disassembled
days after infection
with AdGFP-HBV,
the(HBcAg)
microchannels
AdGFP-HBV,
microchannels
were
and Hepatitis
B core antigen
was
were
disassembled
and
Hepatitis
B
core
antigen
(HBcAg)
was
detected
as
described
in
the
Material
and
detected as described in the Material and Methods section (compare Figure 4a,b). Approximately
Methods
section
(compare
Figure
4a,b).
Approximately
73.3%
of
the
hepatocytes
expressed
HBcAg,
73.3% of the hepatocytes expressed HBcAg, as indicated by immunofluorescence analysis; the greater
as indicated
immunofluorescence
greater number
hepatocytesmay
expressing
number ofbyhepatocytes
expressing analysis;
HBcAg, the
as compared
to GFPof expression,
indicateHBcAg,
that
as compared
to GFP
expression,
may indicate
that secreted
HBVinitially
could infect
neighboring
hepatocytes
secreted HBV
could
infect neighboring
hepatocytes
that were
uninfected
by AdGFP-HBV
that
were
uninfected now
by AdGFP-HBV
andOverall,
that these
hepatocytes
nowindicated
express HBcAg.
and
thatinitially
these hepatocytes
express HBcAg.
these
initial studies
that the Overall,
small
amount
primary
human hepatocytes
cultured
in of
the
microchannel
be infected
with in
thethe
these
initialofstudies
indicated
that the small
amount
primary
humancould
hepatocytes
cultured
recombinantcould
adenovirus
and with
express
HBV proteins,
where expression
of these
proteins where
was
microchannel
be infected
the recombinant
adenovirus
and express
HBV proteins,
controlled
HBV
transcription
promoters
that transcription
are sensitive promoters
to the differentiation
statustoofthe
expression
of by
these
proteins
was controlled
by HBV
that are sensitive
hepatocytes.
differentiation status of hepatocytes.

Figure
4. 4.
Immunofluorescence
in primary
primaryhuman
humanhepatocytes
hepatocytes
infected
with
HBV.
Figure
Immunofluorescencestaining
stainingof
of HBcAg
HBcAg in
infected
with
HBV.
DAPI
nuclear
stainingdye
dyefor
forthe
thesame
sameset
set of
of cells was
(a)(a)
Control
(Mock):
TheThe
DAPI
nuclear
staining
was used
usedfor
forDNA
DNAstaining.
staining.
Control
(Mock):
primary
human
hepatocytesco-cultured
co-cultured with
with bovine
bovine aortic
aortic endothelial
viral
primary
human
hepatocytes
endothelialcells
cells(BAECs)
(BAECs)without
without
viral
infection
underflow
flowconditions
conditions in
in the
the dual
dual microchannel
(b)(b)
AdGFP-HBV
waswas
usedused
as a as
infection
under
microchannelon
onday
day14;14;
AdGFP-HBV
control to
to ensure
ensure that
that the
the hepatocytes
hepatocytes were
capable
of of
a control
were viable,
viable,susceptible
susceptibletotoa aviral
viralinfection,
infection,and
and
capable
expressing
HBV
proteins.
HBcAg
in
AdGFP-HBV
infected
hepatocytes
was
detected
with
Hepatitis
expressing HBV proteins. HBcAg in AdGFP-HBV infected hepatocytes was detected with Hepatitis B
B antibody
core antibody
(HBcAb)
14; (c)infection
Direct infection
with
HBV.inHBcAg
in HBV-infected
core
(HBcAb)
at dayat14;day
(c) Direct
with HBV.
HBcAg
HBV-infected
hepatocytes
hepatocytes
was
detected
with
HBcAb
at
day
14.
Scale
bar:
200
μm.
was detected with HBcAb at day 14. Scale bar: 200 µm.

3.3. HBV Infection and Replication in Primary Human Hepatocytes in Microchannels
3.3. HBV Infection and Replication in Primary Human Hepatocytes in Microchannels
We next sought to demonstrate the utility of our system for studies with hepatotropic viruses
We next sought to demonstrate the utility of our system for studies with hepatotropic viruses by
by testing whether primary human hepatocytes co-cultured with BAECs in our microchannel system
testing whether primary human hepatocytes co-cultured with BAECs in our microchannel system
could be directly infected by HBV. HBV infection of primary human hepatocytes is sensitive to the
could
be directlystatus
infected
byhepatocytes
HBV. HBV and
infection
of primary
human
hepatocytes
is sensitive
toisthe
differentiation
of the
the expression
of the
HBV cell
surface receptor,
which
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differentiation status of the hepatocytes and the expression of the HBV cell surface receptor, which is
known to be lost
lost when
whenhuman
humanhepatocytes
hepatocytesde-differentiate
de-differentiate[41].
[41].InInaddition,
addition,HBV
HBV
typically
replicates
typically
replicates
at
at
low
levels
in hepatocytes
requiring
prolonged
incubation
of differentiated
hepatocytes,
as to
low
levels
in hepatocytes
requiring
prolonged
incubation
of differentiated
hepatocytes,
so as toso
achieve
achieve
of replication
that areforsufficient
detection
as secreted
HBVWe
virions
[5,42].
We
directly
infected
levels of levels
replication
that are sufficient
detectionfor
as secreted
HBV
virions [5,42].
directly
primary human
hepatocytes
on and
day then
2 after
platingHBV
and replication
then analyzed
primary infected
human hepatocytes
with HBV
on day 2with
afterHBV
plating
analyzed
and
HBV
replication
and
expression
ofthis
HBV
core protein
in this
of HBcAg
was also
expression
of HBV
core
protein in
system;
expression
of system;
HBcAg expression
was also used
as one indicator
used
as one indicator
infection
efficiency.
The HBcAg
in HBV-infected
primary human
hepatocytes
of infection
efficiency.ofThe
HBcAg
in HBV-infected
primary
human hepatocytes
was detected
with
was
detected
with
Hepatitis
B
core
antibody
(HBcAb)
at
day
14
(compare
Figure
4a,c).
HBcAg
Hepatitis B core antibody (HBcAb) at day 14 (compare Figure 4a,c). HBcAg was not detected inwas
the
not
detected
in the
control
primary human
(Figure
4a). This analysis
demonstrated72.9%
that
control
primary
human
hepatocytes
(Figure hepatocytes
4a). This analysis
demonstrated
that approximately
approximately
of hepatocytes
the microchannel
wereof HBV-infected;
the analysis
of
of hepatocytes in72.9%
the microchannel
were in
HBV-infected;
the analysis
immunofluorescent
images was
immunofluorescent
images
was
done
using
ImageJ.
Figures
4a
and
c
are
representative
of
one
done using ImageJ. Figure 4a,c are representative of one experiment, but similar results were obtained
experiment,
similar results were obtained in a replicate analysis.
in a replicatebut
analysis.
To further determine whether HBV can both infect and replicate in the cultured primary human
hepatocytes co-cultured with BAECs in our microchannel system, we analyzed secretion of replicated
replicated
HBV into the cell culture medium by collecting cell culture supernatants at the indicated time points
from the microchannels. HBV
HBV genomes
genomes were
were isolated
isolated from
from the
the supernatants
supernatants collected
collected from
from the
the cells,
cells,
and the genome was detected by PCR and
and gel
gel electrophoresis
electrophoresis as
as described
described in
in Section
Section 2.6.
2.6. HBV
genomes from the HBV-infected hepatocytes were detected (Figure 5, Lane 4) and were identical in
size to the band from the positive control (Figure 5, Lane 6). HBV was not detected in the negative
control (Figure 5, Lane 1). Also,
Also, HBV
HBV was not detected in supernatants collected from uninfected
control primary human hepatocytes (Figure 5, Lane 2). As
As an
an additional
additional positive
positive control
control for the
isolation of
from
HepG2.215,
which
is
of HBV
HBV from
fromcell
cellculture
culturesupernatants,
supernatants,we
wecollected
collectedsupernatant
supernatant
from
HepG2.215,
which
the
established
cellcell
line
that
produced
infectious
HBV.
A HBV-specific
PCR
product
was
detected
in
is the
established
line
that
produced
infectious
HBV.
A HBV-specific
PCR
product
was
detected
the
supernatant
from
HepG2.215
cells
(Figure
in the
supernatant
from
HepG2.215
cells
(Figure5,5,Lane
Lane5).
5).These
TheseHBV-specific
HBV-specific PCR
PCR products
products were
identical in size to the band from the positive control (Figure 5, Lane
Lane 6).
6). Thus, the results of this
analysis confirmed that HBV-specific PCR products were detected only in cell-culture supernatants
from positive controls or from primary human
human hepatocytes
hepatocytes infected
infected with
with HBV.
HBV. Importantly, HBV is
hepatotropic, and the expression of HBV RNA transcripts and HBV replication is dependent on the
expression of hepatocyte-specific factors. Hence, the detection of HBV replication in our microfluidic
platform serves as a confirmation that the differentiation status and functions of hepatocytes were
retained throughout the course of our study.
study.

Figure 5. PCR analysis
analysis of supernatant samples
samples from the co-culture of primary human hepatocytes
liver-sinusoid-on-a-chip was performed for the detection of secreted HBV from the
and BAECs on the liver-sinusoid-on-a-chip
water; Lane 2: mock
mock (supernatants collected from hepatocytes without
infected hepatocytes. Lane 1: water;
viral infection at day 22); Lane 3: DNA ladder; Lane 4: supernatants from hepatocytes infected with
supernatants obtained
obtained from HepG2.215;
HepG2.215; and Lane 6: positive
positive control
control of HBV
HBV (day 22); Lane 5: supernatants
plasmid. As aa positive
control
for
a
HBV
gene
expression
analysis,
a
plasmid
containing
a cDNA
of the
positive control for a HBV gene expression analysis, a plasmid containing
a cDNA
of
HBV
genome
waswas
used.
the
HBV
genome
used.

Although our experiments have a drawback in terms of the species discrepancy caused by coculturing human hepatocytes and BAECs, these studies demonstrate the utility of systems in which
the long-term maintenance of human hepatocyte differentiation status can be retained so that the
system can be used for studies of human hepatotropic viruses. In future studies, we will need to
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Although our experiments have a drawback in terms of the species discrepancy caused by
co-culturing human hepatocytes and BAECs, these studies demonstrate the utility of systems in
which the long-term maintenance of human hepatocyte differentiation status can be retained so
that the system can be used for studies of human hepatotropic viruses. In future studies, we will
need to validate the HBV replication study described here in a co-culture system of primary human
hepatocytes and primary human liver sinusoidal endothelial cells. Moreover, from the aspect of the
pathophysiology of viral infection in vivo, it may also be necessary to infect hepatocytes with HBV
through the endothelial cell layer by introducing HBV into the microchannel where endothelial cells
are cultured. However, even considering the requirement of these future modifications, we have
presented a human-liver-sinusoid-on-a-chip model, wherein primary human hepatocytes that are
co-cultured with BAECs in the microfluidic platform can be used in HBV replication studies. Moreover,
we believe that our microfluidic co-culture system can be extended to long-term studies involving
other viral infections of the human hepatocytes.
4. Conclusions
We have developed a human liver model where primary human hepatocytes and BAECs are
co-cultured on opposite sides of a microporous membrane in a dual microfluidic platform. Primary
human hepatocytes co-cultured with BAECs retained their morphology and viability for up to 26 days.
The primary human hepatocytes cultured in the microfluidic channel were infected with HBV. The
HBcAg of the primary human hepatocytes infected with HBV was detected with an anti-HBcAg
antibody by immunofluorescence. Moreover, secreted HBV was detected by measuring cell-secreted
HBV DNA from the supernatants collected from the HBV-infected hepatocytes. The ability to detect
HBV replication in our microfluidic platform serves as a confirmation that the differentiation and
functional status of hepatocytes was retained throughout the course of our experimentation.
Overall, we have presented a novel human-liver-sinusoid-on-a-chip model system wherein
primary human hepatocytes are co-cultured with BAECs in the microfluidic channels and have
demonstrated the utility of this model system for HBV-related studies. We believe that our microfluidic
culture system can be extended to long-term studies involving viral infections of primary human
hepatocytes that were previously not possible due to the rapid loss of function of primary hepatocytes
in conventional cell-culture systems. For example, it may be possible to apply our liver model to study
chronic HBV infection that is characterized by the persistence of HBsAg for the long-term as well as
the persistence of HBV cccDNA. Finally, we believe that our human-liver-sinusoid-on-a-chip could
also find numerous applications in other liver-related research and drug development.
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